ALK and inflammatory myofibroblastic tumor: Although selective ALK inhibitors are being evaluated in clinical trials, most of these trials focus on ALK+ solid tumors such as non-small cell lung cancer (NSCLC), neuroblastoma, and inflammatory myofibroblastic tumor [16-18].